Jim Cramer on ImmunityBio: “I Really Think That You Have to Take Profits in Some of That”

Company Overview - ImmunityBio, Inc. (NASDAQ:IBRX) develops therapies aimed at enhancing the immune system to combat infectious diseases and various cancers [2]. Stock Performance - The stock has experienced significant gains, with an increase of over 130% since a recent comment was aired, and a year-to-date rise of over 220% [3]. Analyst Opinions - Jim Cramer expressed skepticism about ImmunityBio, indicating that the company has been unprofitable for an extended period and does not favor the stock as a good investment [2]. - Cramer suggested that investors should consider taking profits on the stock due to its substantial price increase following an FDA meeting [1]. Investment Comparison - While acknowledging the potential of IBRX, it is noted that certain AI stocks may present greater upside potential and lower downside risk compared to ImmunityBio [3].